BSN Tracker

pioglitazone

Brand: Actos

⚠ BBW Prototype Drug
Drug Class: thiazolidinedione
Drug Family: antidiabetic
Subclass: PPAR-gamma agonist insulin sensitizer
Organ Systems: endocrine

Mechanism of Action

Activates nuclear PPAR-gamma receptors in adipose tissue, skeletal muscle, and liver, increasing transcription of genes for insulin-sensitive glucose transporters (GLUT4) and free fatty acid metabolism. Improves insulin sensitivity in peripheral tissues and reduces hepatic glucose output without stimulating insulin secretion.

PPAR-gamma (peroxisome proliferator-activated receptor gamma)

Indications

  • type 2 diabetes mellitus (monotherapy or combination)
  • non-alcoholic steatohepatitis (NASH) — off-label

Contraindications

  • heart failure (NYHA class III–IV)
  • active bladder cancer
  • history of bladder cancer
  • hepatic impairment

Adverse Effects

Common

  • weight gain (fluid retention and adipogenesis)
  • edema
  • headache

Serious

  • heart failure exacerbation (fluid retention)
  • bladder cancer (long-term use)
  • bone fractures (women — distal extremities)
  • macular edema

Pharmacokinetics (ADME)

Absorption oral bioavailability ~83%
Distribution >99% protein bound (albumin)
Metabolism hepatic via CYP2C8 (major) and CYP3A4
Excretion fecal (primarily); minor renal
Half-life 3–7 hours (pioglitazone); active metabolites: 16–24 hours
Onset days to weeks
Peak 2 hours
Duration ongoing with daily use
Protein Binding >99%
Vd 0.63 L/kg

Drug Interactions

Drug / Agent Mechanism Severity
gemfibrozil CYP2C8 inhibition doubles pioglitazone exposure major
rifampin CYP induction reduces pioglitazone levels by 54% major
oral contraceptives CYP3A4 induction may reduce OCP efficacy moderate

Nursing Considerations

  1. Assess for signs of heart failure (dyspnea, rapid weight gain, edema) at every visit; hold if heart failure symptoms develop.
  2. Weigh patients weekly initially; edema and fluid retention are common adverse effects.
  3. Monitor LFTs before initiation and periodically; do not use if ALT >2.5× ULN.
  4. Counsel female patients about increased fracture risk (distal extremities — wrist, foot, ankle); recommend adequate calcium and vitamin D.

Clinical Pearls

  • Pioglitazone is the only TZD with evidence for cardiovascular benefit (PROactive trial: reduced secondary MACE), though this is partially offset by heart failure risk.
  • Rosiglitazone (another TZD) was restricted due to increased myocardial infarction risk; pioglitazone does not share this risk and is now the preferred TZD.

Safety Profile

Pregnancy avoid
Lactation avoid
Renal Adjustment Not required
Hepatic Adjustment Required
TDM Not required

Concordance Terms

Cross-referenced clinical concepts — click any term to see all content where it appears.

Non-alcoholic Steatohepatitis (NASH) — Off-label Thiazolidinedione Type 2 Diabetes Mellitus (monotherapy Or Combination)
← Back to Medications